Melt Pharmaceuticals

Melt Pharmaceuticals is a US specialty pharmaceutical company — carved out from Harrow, Inc. in 2019 and subsequently re-acquired — that developed MELT-300, a sublingual fast-dissolving tablet combining ketamine (50 mg) and midazolam (3 mg) for opioid-free procedural sedation using Catalent's Zydis® technology. The company reported positive Phase 3 topline results for cataract surgery sedation in November 2024, positioning MELT-300 for FDA regulatory submission.